Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01956799

Acronym

BIOFER12

Enrollment

100

Registered

2013-10-08

Start date

2013-05-31

Completion date

2019-12-31

Last updated

2023-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aplastic Anemia, Myelodysplasia, Myelofibrosis

Keywords

MDS, PMF, CMML, AA

Brief summary

The study aims to evaluate the molecular mechanism underlying the erythroid response observed in some patients with myelodysplasia, myelofibrosis and aplastic anemia treated with Deferasirox or Deferoxamina.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients aged 18 and older 2. Diagnosis of Myelodysplasia, myelofibrosis or aplastic anemia 3. transfusion-dependent anemia undergoing chelation therapy with deferasirox or deferoxamine

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
To assess the molecular mechanism underlying the erythroid response	12 months	The primary outcome is to evaluate the molecular mechanism underlying the erythroid response (hemogoblin increase and reduction or elimination of trasfusion dependence) observed in some patients with myelodysplasia, myelofibrosis and aplastic anemia treated with Deferasirox or Deferoxamina

Countries

Italy

Outcome results